XML 53 R62.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segmental Reporting (Tables)
 12 Months Ended
Dec. 31, 2012
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
 SPHGTRMAll OtherTotal
2012$’M$’M$’M$’M$’M
 _______________________________________________________
Product sales2,834.91,418.0153.8- 4,406.7
Royalties148.8- - 92.8241.6
Other revenues31.71.2- -32.9
 _________________________________________________________
Total revenues3,015.41,419.2153.892.84,681.2
 _________________________________________________________
      
Cost of product sales(1)345.4240.459.6- 645.4
Research and development(1)617.4329.119.0- 965.5
Selling, general and administrative(1)1,354.1384.4161.8213.72,114.0
Gain on sale of product rights(18.1)- - - (18.1)
Integration and acquisition costs12.10.512.6- 25.2
 ___________________________________________________________
Total operating expenses2,310.9954.4253.0213.73,732.0
 ___________________________________________________________
Operating income/(loss)704.5464.8(99.2)(120.9)949.2
 ___________________________________________________________
      
Total assets2,370.81,941.6945.82,059.07,317.2
Long-lived assets(2)138.8698.236.283.9957.2
Capital expenditure on long-lived assets(2)64.542.19.729.5146.2
 _________________________________________________________

(1) Depreciation from manufacturing plants ($31.5 million) and amortization of favorable manufacturing contracts ($0.7 million) is included in Cost of product sales; depreciation of research and development assets ($22.5 million) and impairment of IPR&D intangible assets in the SP reporting segment ($71.2 million) is included in Research and development; and all other depreciation, amortization and impairment of ($380.6 million) is included in Selling, general and administrative.

(2) Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments).

 SPHGTRMAll OtherTotal
2011$’M$’M$’M$’M$’M
 _______________________________________________________
Product sales2,615.61,229.3105.3- 3,950.2
Royalties199.6- - 83.9283.5
Other revenues24.51.2- 4.029.7
 _________________________________________________________
Total revenues2,839.71,230.5105.387.94,263.4
 _________________________________________________________
      
Cost of product sales(1)351.7200.036.4- 588.1
Research and development(1)449.1315.46.2- 770.7
Selling, general and administrative(1)1,131.3340.664.4215.11,751.4
Loss on sale of product rights6.0- - - 6.0
Reorganization costs11.8- - 12.524.3
Integration and acquisition costs0.1- 13.6- 13.7
 ___________________________________________________________
Total operating expenses1,950.0856.0120.6227.63,154.2
 ___________________________________________________________
Operating income/(loss)889.7374.5(15.3)(139.7)1,109.2
 ___________________________________________________________
      
Total assets2,421.71,849.4967.71,141.46,380.2
Long-lived assets(2)126.8720.822.963.2933.7
Capital expenditure on long-lived assets(2)54.4129.41.518.9204.2
 _________________________________________________________

(1) Depreciation from manufacturing plants ($39.8 million) and amortization of favorable manufacturing contracts ($1.7 million) is included in Cost of product sales; depreciation of research and development assets ($25.2 million) and impairment of IPR&D intangible assets in the SP reporting segment ($16.0 million) is included in Research and development; and all other depreciation, amortization and impairment ($228.1 million) is included in Selling, general and administrative.

(2) Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments).

 SPHGTRMAll OtherTotal
2010$’M$’M$’M$’M$’M
 _______________________________________________________
Product sales2,219.2909.0- - 3,128.2
Royalties173.3- - 154.8328.1
Other revenues7.12.6- 5.114.8
 _________________________________________________________
Total revenues2,399.6911.6- 159.93,471.1
 _________________________________________________________
      
Cost of product sales(1)332.1129.3- 2.0463.4
Research and development(1)348.9312.2- 0.4661.5
Selling, general and administrative(1)1,035.8297.7- 192.81,526.3
Gain on sale of product rights(16.5)- - - (16.5)
Reorganization costs13.0- - 21.334.3
Integration and acquisition costs8.0- - - 8.0
 ___________________________________________________________
Total operating expenses1,721.3739.2- 216.52,677.0
 _________________________________________________________
Operating income/(loss)678.3172.4- (56.6)794.1
 ___________________________________________________________
      
Total assets2,483.51,786.9- 1,117.25,387.6
Long-lived assets(2)154.7655.4- 47.3857.4
Capital expenditure on long-lived assets(2)21.8281.1- 12.9315.8
 _________________________________________________________

(1) Depreciation from manufacturing plants ($38.1 million) and amortization of favorable manufacturing contracts ($1.7 million) is included in Cost of product sales; depreciation of research and development assets ($19.0 million) is included in Research and development; and all other depreciation and amortization ($238.3 million) is included in Selling, general and administrative.

(2) Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments).
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
 201220112010
Year to December 31,$’M$’M$’M
 _________________________________
Ireland 20.621.121.1
United Kingdom207.0219.9203.9
North America 3,159.92,867.12,333.1
Rest of World1,293.71,155.3913.0
 ____________________________________
Total revenues4,681.24,263.43,471.1
 ____________________________________

 20122011
Year to December 31,$’M$’M
 ______________________
Ireland 5.22.9
United Kingdom72.273.7
North America 861.0841.0
Rest of World18.816.1
 ________________________
Total 957.2933.7
 ________________________
Schedule of Revenue by Major Customers by Reporting Segments
       
 201220122011201120102010
Year to December 31,$’M% product revenue$’M% product revenue$’M% product revenue
 __________________________________________________________________
Cardinal Health Inc.1,035.724923.923791.225
McKesson Corp.835.919742.919574.319
 _____________________________________________________________________
       
Schedule of Trade Receivables by Major Customers by Reporting Segments
       
Amounts outstanding as at December 31, in respect of these material customers were as follows:
       
     20122011
December 31,    $’M$’M
     ______________________
Cardinal Health Inc.    166.1172.1
McKesson Corp.    127.4101.4
     _______________________
       
Schedule of Segment Revenue from Major Products
 201220112010
 $’M$’M$’M
 _________________________________
    
Specialty Pharmaceuticals   
VYVANSE1,029.8805.0634.2
ADDERALL XR429.0532.8360.8
INTUNIV 287.8223.0165.9
EQUASYM 29.219.922.0
DAYTRANA- - 49.4
LIALDA / MEZAVANT399.9372.1293.4
PENTASA265.8251.4235.9
RESOLOR11.86.10.3
FOSRENOL172.0166.9182.1
XAGRID97.290.687.3
Other112.4147.8187.9
 ____________________________________
 2,834.92,615.62,219.2
 ____________________________________
    
Human Genetic Therapies   
REPLAGAL497.5 475.2 351.3
ELAPRASE497.6 464.9 403.6
VPRIV306.6 256.2 143.0
FIRAZYR116.3 33.0 11.1
 ____________________________________
 1,418.01,229.3909.0
 ____________________________________
    
Regenerative Medicine   
DERMAGRAFT153.8105.3-
 ____________________________________
 153.8105.3-
 ____________________________________
    
 4,406.73,950.23,128.2
 ____________________________________